<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597515</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01199-48</org_study_id>
    <nct_id>NCT04597515</nct_id>
  </id_info>
  <brief_title>Reduction of Breast Enlargement Using the Da Vinci Xi Robot</brief_title>
  <acronym>R-HTM-R</acronym>
  <official_title>Reduction of Breast Enlargement Using the Da Vinci Xi Robot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital Privé d'Antony - Dr Dunet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast enlargement reductions are frequent interventions. One of the main issue associated&#xD;
      with this surgery remains the ransom scar, wide at the periareolar level, vertical at the&#xD;
      subareolar level and in the submammary groove.&#xD;
&#xD;
      The expected result is to achieve a reduction in breast enlargement with no visible scar&#xD;
      using Da Da Vinci Xi robot.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast enlargement reductions are frequent interventions. One of the main issue associated&#xD;
      with this surgery remains the ransom scar, wide at the periareolar level, vertical at the&#xD;
      subareolar level and in the submammary groove. In addition, this intervention remains subject&#xD;
      to the vagaries of hypertrophic or even keloid scarring, especially in young women.&#xD;
&#xD;
      The current research project is based on the hypothesis that the same technique could be used&#xD;
      in the context of a reduction of breast enlargement on a smaller surface allowing the&#xD;
      determination of a perimammary &quot;halo&quot; of scar retraction. The project consists in removing a&#xD;
      breast disc at the base, thus causing a sagging skin cut of 2 to 3 cm but this time,&#xD;
      circular.&#xD;
&#xD;
      The expected result is to achieve a reduction in breast enlargement with no visible scar,&#xD;
      using Da Vinci Xi robot.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Visible Scare</measure>
    <time_frame>3 months</time_frame>
    <description>The main judgment criterion for the scar balance will be a photograph of the breasts at 3 months to describe the number of visible scars. Aspect and position.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacity of the reduction (weight)</measure>
    <time_frame>day of surgery</time_frame>
    <description>- The weight of the exeresis (more than 300g per side which corresponds according to calculation to a gland disc about 2 cm thick on an extended conical breast of 13cm for the base)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Back Pain</measure>
    <time_frame>3 months</time_frame>
    <description>The pain score on the EVA scale (score from 0 no pain to 10 max pain) will be described</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin retraction</measure>
    <time_frame>at 3 months</time_frame>
    <description>- Post-operative skin retraction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visible scare number</measure>
    <time_frame>1 year</time_frame>
    <description>number of visible scare based on photos analysis</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Breast Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Robot Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robot Breast reduction surgery</intervention_name>
    <description>Breast reduction surgery, using a robot by removing a breast disc at the base</description>
    <arm_group_label>Robot Reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over the age of 18&#xD;
&#xD;
          -  Category 1 or 2 according to the classification of Regnault&#xD;
&#xD;
          -  Breast size cup c or more&#xD;
&#xD;
          -  Areola &quot;looking in front&quot;, ie a distance between point A (at noon at the top of the&#xD;
             areola) at the mid-sternal point of about 16 cm to 24 cm&#xD;
&#xD;
          -  Ptosis (distance between the lowest part of the breast and the furrow under the&#xD;
             breast) to a maximum of 7cm (measurement in sitting position)&#xD;
&#xD;
          -  Expected correction of ptosis by half with reduction of 1 to 3 cup sizes&#xD;
&#xD;
          -  Good quality thick skin&#xD;
&#xD;
          -  Affiliated patient or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient requesting breast reduction&#xD;
&#xD;
          -  Patient who signed free and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Areola &quot;look down&quot;; point A more than 25 cm&#xD;
&#xD;
          -  Ptose greater than and equal to 8 cm&#xD;
&#xD;
          -  Thin skin&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Patient on anti-coagulant&#xD;
&#xD;
          -  Patient participating in another clinical study&#xD;
&#xD;
          -  Protected patient: adults under guardianship, curatorship or other legal protection,&#xD;
             deprived of their liberty by judicial or administrative decision;&#xD;
&#xD;
          -  Pregnant, lactating woman&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Dunet, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramsay santé</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean François OUDET</last_name>
    <phone>+33683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MH barba</last_name>
    <phone>+33664888704</phone>
    <phone_ext>+330664888704</phone_ext>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Privé d'Antony</name>
      <address>
        <city>Antony</city>
        <state>IDF</state>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JF OUDET</last_name>
      <phone>+33683346567</phone>
      <phone_ext>+33683346567</phone_ext>
      <email>jf.oudet@ecten.eu</email>
    </contact>
    <contact_backup>
      <last_name>MH barba</last_name>
      <phone>+330664888704</phone>
      <phone_ext>+330664888704</phone_ext>
      <email>mh.barba@ecten.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Dunet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast reduction</keyword>
  <keyword>perimammary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

